Development Drugs Genetic Analysis Genetics 
Pharmaceutical Technology
MAY 22, 2023
Thermo Fisher Scientific has expanded its sterile manufacturing and research capabilities in the Asia-Pacific region with the opening of a new sterile drug facility in Singapore. The new good manufacturing practices facility was established with support from the Singapore Economic Development Board.
Drug Discovery World
FEBRUARY 28, 2023
As we turn our focus to new potential applications and disease areas for the platform, scientists and companies must consider the potential life-saving impact on rare, inherited diseases, says Archana Gupta , PhD, staff scientist in genetic sciences at Thermo Fisher Scientific.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
MARCH 13, 2023
Bauer, Senior Regulatory Drug Expert & James E. Valentine — Incorporating patient and caregiver experiences into every phase of drug development has become increasingly prioritized during both development and review ( see, e.g. , previous coverage here ). There have been challenges in gene therapy development.
The Pharma Data
OCTOBER 27, 2020
Food and Drug Administration (FDA). Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY ® System. SAN DIEGO , Oct. “To address the crisis presented by COVID-19, labs need to cost-effectively process large numbers of samples. .” Source link.
Delveinsight
FEBRUARY 25, 2021
Beam adds to drug delivery stable with USD 120 Million GuideTx buy. Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. Beam employs three approaches to deliver its genetic medicines to cells.
Drug Discovery World
APRIL 21, 2023
Atrandi Biosciences’ novel technology platform enables researchers to gain insights into the biology of single cells, offering immediate applications in single-cell sequencing, drug and antibody discovery, functional metagenomics, microbial analysis, directed evolution, and synthetic biology. It will be led by Björn C.
pharmaphorum
NOVEMBER 16, 2022
It’s one of the most common causes of blindness across Europe and across the United States, and many developed countries around the world. That’s why there’s a lot of interest around this particular molecule and around this development programme.”. When we do that, we call it a perilesional analysis.
Expert insights. Personalized for you.
147 
Let's personalize your content